Organogenesis Holdings Inc. (ORGO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US68621F1021
Organogenesis Holdings Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 564.17 m USD |
| Operating income | 44.69 m USD |
| EBIT | 44.69 m USD |
| Net income | 37.03 m USD |
| Diluted EPS – continuing operations | 0.15 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
More stocks
- Panion & BF Biotech Inc (1760.TW)
- Boab Metals Ltd (BML.AX)
- Schwager (SCHWAGER.SN)
- Northcliff Resources Ltd (NCF.TO)
- Exel Composites Oyj (EXEL.HE)
- Legacy Ventures International Inc (LGYV)
- PT Intra GolfLink Resorts Tbk (GOLF.JK)
- Ubiqconn Technology, Inc. (6928.TW)
- Arcticzymes Technologies ASA (AZT.OL)
- Daewon Pharmaceutical Co. Ltd. (003220.KS)
- Audinate Group Ltd (AD8.AX)
- Food Moments PCL (FM.BK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.